Published online before print November 21, 2007, doi: 10.1161/ATVBAHA.107.153965
© 2008 American Heart Association, Inc.
Clinical and Population Studies |
Vitamin E Supplementation Reduces Cardiovascular Events in a Subgroup of Middle-Aged Individuals With Both Type 2 Diabetes Mellitus and the Haptoglobin 2-2 Genotype
A Prospective Double-Blinded Clinical Trial
From Clalit Health Services (U.M., C.S., L.B., M.K., A.K., A.R.), Haifa and Western Galilee, Israel; Technion Faculty of Medicine (S.B., R.M.L., Y.A., J.A., A.P.L.), Technion-Israel Institute of Technology, Haifa, Israel; Cardiology Department (D.A.), Rambam Medical Center, Haifa, Israel; Internal Medicine (S.K., Y.L.), Rambam Medical Center, Haifa, Israel; and PharmaBrains Israel (M.L.), Tel Aviv, Israel.
Correspondence to Andrew P. Levy, MD, PhD, Technion Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel 31096. E-mail alevy{at}tx.technion.ac.il
Abstract
Objective— Clinical trials of vitamin E have failed to demonstrate a decrease in cardiovascular events. However, these studies did not address possible benefit to subgroups with increased oxidative stress. Haptoglobin (Hp), a major antioxidant protein, is a determinant of cardiovascular events in patients with Type 2 diabetes mellitus (DM). The Hp gene is polymorphic with 2 common alleles, 1 and 2. The Hp 2 allelic protein product provides inferior antioxidant protection compared with the Hp 1 allelic product. We sought to test the hypothesis that vitamin E could reduce cardiovascular events in DM individuals with the Hp 2-2 genotype, a subgroup that comprises 2% to 3% of the general population.
Methods and Results— 1434 DM individuals 
55 years of age with the Hp 2-2 genotype were randomized to vitamin E (400 U/d) or placebo. The primary composite outcome was myocardial infarction, stroke, and cardiovascular death. At the first evaluation of events, 18 months after initiating the study, the primary outcome was significantly reduced in individuals receiving vitamin E (2.2%) compared with placebo (4.7%; P=0.01) and led to early termination of the study.
Conclusions— Vitamin E supplementation appears to reduce cardiovascular events in individuals with DM and the Hp 2-2 genotype (ClinicalTrials.gov NCT00220831).
We sought to determine whether vitamin E could reduce cardiovascular events in DM individuals with the Hp 2-2 genotype. The primary composite outcome was myocardial infarction, stroke, and cardiovascular death. Cardiovascular events were significantly reduced in individuals receiving vitamin E (2.2%) compared with placebo (4.7%; P=0.01).
Key Words: diabetes mellitus • vitamin E • cardiovascular events • pharmacogenomics • haptoglobin genotype
This article has been cited by other articles:
 |
|
 |
|
  S. E. Belisle, L. S. Leka, J. Delgado-Lista, P. F. Jacques, J. M. Ordovas, and S. N. Meydani Polymorphisms at Cytokine Genes May Determine the Effect of Vitamin E on Cytokine Production in the Elderly J. Nutr., October 1, 2009; 139(10): 1855 - 1860. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Xu and M.-H. Zou Molecular Insights and Therapeutic Targets for Diabetic Endothelial Dysfunction Circulation, September 29, 2009; 120(13): 1266 - 1286. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Dotan, I. Pinchuk, D. Lichtenberg, and M. Leshno Decision Analysis Supports the Paradigm That Indiscriminate Supplementation of Vitamin E Does More Harm than Good Arterioscler Thromb Vasc Biol, September 1, 2009; 29(9): 1304 - 1309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Meydani and A. Azzi Diabetes risk: antioxidants or lifestyle? Am. J. Clinical Nutrition, August 1, 2009; 90(2): 253 - 254. [Full Text] [PDF]
|
|
|
|
 |
|
 P. R. Moreno, J. Sanz, and V. Fuster Promoting Mechanisms of Vascular Health: Circulating Progenitor Cells, Angiogenesis, and Reverse Cholesterol Transport J. Am. Coll. Cardiol., June 23, 2009; 53(25): 2315 - 2323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. Nakhoul, R. Miller-Lotan, H. Awad, R. Asleh, K. Jad, N. Nakhoul, R. Asaf, N. Abu-Saleh, and A. P. Levy Pharmacogenomic effect of vitamin E on kidney structure and function in transgenic mice with the haptoglobin 2-2 genotype and diabetes mellitus Am J Physiol Renal Physiol, April 1, 2009; 296(4): F830 - F838. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Steinberg The LDL modification hypothesis of atherogenesis: an update J. Lipid Res., April 1, 2009; 50(Supplement): S376 - S381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Asleh, S. Blum, S. Kalet-Litman, J. Alshiek, R. Miller-Lotan, R. Asaf, W. Rock, M. Aviram, U. Milman, C. Shapira, et al. Correction of HDL Dysfunction in Individuals With Diabetes and the Haptoglobin 2-2 Genotype Diabetes, October 1, 2008; 57(10): 2794 - 2800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. R. Moreno, K. R. Purushothaman, M. Purushothaman, P. Muntner, N. S. Levy, V. Fuster, J. T. Fallon, P. A. Lento, A. Winterstern, and A. P. Levy Haptoglobin Genotype Is a Major Determinant of the Amount of Iron in the Human Atherosclerotic Plaque J. Am. Coll. Cardiol., September 23, 2008; 52(13): 1049 - 1051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Blum, U. Milman, C. Shapira, R. Miller-Lotan, L. Bennett, M. Kostenko, M. Landau, S. Keidar, Y. Levy, A. Khemlin, et al. Dual Therapy With Statins and Antioxidants Is Superior to Statins Alone in Decreasing the Risk of Cardiovascular Disease in a Subgroup of Middle-Aged Individuals With Both Diabetes Mellitus and the Haptoglobin 2-2 Genotype Arterioscler Thromb Vasc Biol, March 1, 2008; 28(3): e18 - e20. [Full Text] [PDF]
|
|